RxDoctor Payments Data

Farah Smith

Family · Douglas, GANPI 1447616461

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 723 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,590in general payments, 2019–2025

Across 723 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Amgen$1K
  • Corcept Therapeutics$1K
  • GSK$921
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$14,25998%
  • Education$3312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,590 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$109,163
MounjaroTirzepatide88$105,895
FarxigaDapagliflozin Propanediol115$101,928
VraylarCariprazine Hcl47$69,076
JardianceEmpagliflozin82$62,116
LinzessLinaclotide90$59,220
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$40,313
EliquisApixaban45$36,530
JanuviaSitagliptin Phosphate48$33,669
KerendiaFinerenone29$30,414
TrulicityDulaglutide18$25,620
MyrbetriqMirabegron45$23,464
Repatha SureclickEvolocumab29$21,206
XareltoRivaroxaban27$19,092
GemtesaVibegron22$17,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess, Creon, Synthroid$1,446$141,594189 claims
Lilly USA, LLCMounjaro, Trulicity$155$131,515106 claims
Novo NordiskOzempic, Rybelsus$1,441$124,016125 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$743$120,231149 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$137$75,991107 claims
GSKTrelegy Ellipta$921$40,31359 claims
PfizerEliquis$1,318$36,53045 claims
MerckJanuvia$124$33,66948 claims
BayerKerendia$268$30,41429 claims
Astellas Pharma US IncMyrbetriq$710$23,46445 claims
Johnson & JohnsonXarelto$234$19,09227 claims
Sumitomo Pharma America, Inc.Gemtesa$181$17,80222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Douglas

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →